神经周围侵犯与帕博利珠单抗治疗头颈鳞癌的生存关系
OBJECTIVE: To determine the relationship between perineural invasion and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on pembrolizumab.…
要点
- 神经周围侵犯与帕博利珠单抗治疗的复发/转移性头颈鳞癌6个月无进展生存期更差独立相关。
- 神经周围侵犯与6个月至进展时间更短相关,但与2年总生存期无显著关联。
- 需未来研究探索神经周围侵犯如何影响免疫治疗反应。
核心结论
- 神经周围侵犯的存在与头颈鳞癌患者接受免疫检查点抑制剂治疗时更差的6个月无进展生存期相关。
主要发现
- 单变量分析中,神经周围侵犯患者6个月无进展生存期更差(p=0.011)。
临床怎么用
- 对于接受帕博利珠单抗治疗的复发/转移性头颈鳞癌患者,神经周围侵犯可提示6个月无进展生存期和至进展时间可能更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the relationship between perineural invasion and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on pembrolizumab. METHODS: This study was a retrospective, observational study performed at a tertiary care academic center. Participants included patients with oral cavity, oropharynx, hypopharynx, and laryngeal head and neck squamous cell carcinoma who began pembrolizumab treatment at UCSF between May 2016 and May 2022. The primary outcome was 6-month progression-free survival and 6-month time-to-progression (TTP). The secondary outcome was 2-year overall survival. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors. RESULTS: One hundred and thirty-three patients with HNSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. Forty (30%) patients had perineural invasion. On univariate analysis, patients with perineural invasion were more likely to have worse 6-month PFS (p = 0.011). After controlling for number of metastatic organs, receipt of concurrent systemic therapy, age, and PDL-1 status, presence of perineural invasion was associated with worse 6-month PFS [HR 3.33 (1.32, 8.41), p = 0.011] and 6-month time to progression (TTP) [HR 2.14 (1.09, 7.38), p = 0.032], but was not significantly associated with 2-year OS [HR 1.35 (0.57, 3.19), p = 0.498]. CONCLUSION: Presence of perineural invasion is associated with poorer 6-month progression-free survival on ICI in patients with HNSCC. Future studies should further explore how perineural invasion may alter response to immunotherapy.
引用
- Truong AA, Ho S, Lee RH, et al. Perineural Invasion and Survival in Pembrolizumab-Treated Head and Neck Squamous Cell Carcinoma. Laryngoscope. 2026. PMID: 41482826. doi:10.1002/lary.70350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。